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Background: 2-8% of all children aged between 6 months and 5 years have febrile seizures. Often these seizures
cease spontaneously, however depending on different national guidelines, 20-40% of the patients would need
therapeutic intervention. For seizures longer than 3-5 minutes application of rectal diazepam, buccal midazolam or
sublingual lorazepam is recommended. Benzodiazepines may be ineffective in some patients or cause prolonged
sedation and fatigue. Preclinical investigations in a rat model provided evidence that febrile seizures may be
triggered by respiratory alkalosis, which was subsequently confirmed by a retrospective clinical observation. Further,
individual therapeutic interventions demonstrated that a pCO2-elevation via re-breathing or inhalation of 5% CO2
instantly stopped the febrile seizures. Here, we present the protocol for an interventional clinical trial to test the
hypothesis that the application of 5% CO2 is effective and safe to suppress febrile seizures in children.
Methods: The CARDIF (CARbon DIoxide against Febrile seizures) trial is a monocentric, prospective, double-blind,
placebo-controlled, randomized study. A total of 288 patients with a life history of at least one febrile seizure will be
randomized to receive either carbogen (5% CO2 plus 95% O2) or placebo (100% O2). As recurrences of febrile
seizures mainly occur at home, the study medication will be administered by the parents through a low-pressure
can fitted with a respiratory mask. The primary outcome measure is the efficacy of carbogen to interrupt febrile
seizures. As secondary outcome parameters we assess safety, practicability to use the can, quality of life,
contentedness, anxiousness and mobility of the parents.
Prospect: The CARDIF trial has the potential to develop a new therapy for the suppression of febrile seizures by
redressing the normal physiological state. This would offer an alternative to the currently suggested treatment with
benzodiazepines. This study is an example of academic translational research from the study of animal physiology
to a new therapy.
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Febrile seizures are defined as cerebral seizures occur-
ring in children between 6 months and 5 years of age
that are solely associated with fever and not with CNS
infection or previous neonatal or unprovoked seizures,
and do not meet defining criteria for acute symptomatic
seizures [1]. Febrile seizures are the most common type
of cerebral seizures in childhood and affect between 2-8
% of all children, depending on geographical and ethnic
factors, as well as on ascertainment definitions and me-
thods [2-4]. The peak incidence of febrile seizures is
around 16-18 months-of-age [5-7]. Regarding the dur-
ation of febrile seizures, Hesdorffer et al. investigated
158 children with a first febrile seizure and distinguished
two groups, one with an average duration of 3.8 minutes
(82% of the study population) and a second one with
39.8 minutes (18%). In 38-54% of the children the dur-
ation of febrile seizure was above 5 and 3 minutes,
respectively, and would thus have triggered pharmaco-
logical intervention according to the guidelines [8-10].
In about 30% of affected children febrile seizures are re-
current [11]. Most febrile seizures have a benign progno-
sis, but their occurrence during childhood is associated
with an increased risk of 2.4-8.0% to develop epilepsy
later in life [12,13]. In contrast to simple febrile seizures,
prolonged febrile seizures or febrile status epilepticus
(seizure duration > 30 min) have a substantial higher risk
to cause short- and long-term brain abnormalities. For
example, it has been shown that complex febrile seizures
are associated with an increased T2-signal intensity on
cranial MRI, most likely reflecting acute injury of the
hippocampal formation [14,15]. “Simple” febrile seizures
mainly occur within the first 24 hours of a febrile illness
and only once during a fever period, last less than 15
minutes and do not show a focal component. “Complex”
febrile seizures last longer than 15 minutes, occur sev-
eral times during one fever episode, and may have focal
features. The duration of recurrent febrile seizures is
often longer than that of single ones [11].
In Germany, no commonly agreed and published guide-
lines exist regarding the treatment of febrile seizures, but a
published Italian guideline recommends waiting for the
febrile seizure to cease spontaneously within the first 3
minutes. Only after this “waiting period” benzodiazepines
(rectal diazepam, buccal midazolam, or sublingual loraze-
pam) should be administered as the “standard therapy”,
which will reach pharmacologically active concentrations
in the CNS after 3-5 minutes [9]. However, benzodiaze-
pines are effective in only 60-80% of children with seizures
[16,17]. Furthermore, due to its sedative effect, children
may sleep for the rest of the day. Undesirable strong
sedation and fatigue, headache, ataxia, confusion, antero-
grade amnesia, and paradoxical stimulatory effects are
potential side effects of benzodiazepines. The incidence ofrespiratory depression after the rectal application of diaze-
pam is 5-8% with some patients even requiring mechan-
ical ventilation [18-20]. Additionally, the sedative effect
may impede a precise pediatric assessment and possibly
lead to unnecessary invasive diagnostic procedures such as
a lumbar puncture. As children with febrile seizures are
mainly treated at home, these potential side effects should
be taken into consideration and an alternative to the cur-
rently used pharmacological therapy would be welcome.
Schuchmann et al. reported an animal model, in which
they raised to 40-41°C the body temperature of young
rats aged P8-11 (corresponding to a human developmen-
tal age of 1-5 years) and P22-23 (≈ human 12-18 years)
in a heated chamber [21]. Only all the young rats (P8-
11, n = 29) had cerebral seizures, but none of the older
ones. The authors demonstrated a disproportional in-
crease of the breathing frequency (hyperventilation) in
young rats along with the rise of body temperature.
Hyperventilation led to hypocapnia, subsequent respira-
tory alkalosis, elevation of the intracranial pH, and thus
an increase of the excitability of cortical neurons. To re-
store the normal physiological state, the authors in-
creased the ambient CO2 concentration to 5%. Indeed,
the blood pCO2 normalized and the seizures stopped
within 15-20 seconds, thus verifying the antiepileptic
effect of CO2 under these conditions.
These findings prompted us to investigate, whether
febrile seizures might also be associated with and triggered
by respiratory alkalosis in human patients. In a retrospect-
ive study Schuchmann et al. analyzed the blood gas mea-
surements of 433 children who were admitted to the
pediatric emergency department of the Charité with vari-
ous conditions. They discovered that up to 2 hours after
the febrile seizure the blood pH in children was signifi-
cantly higher and the pCO2 levels lower than in children
admitted for other reasons (e.g. gastroenteritis, upper re-
spiratory tract infection) [22]. Beyond that, individual un-
controlled therapeutic interventions have been reported,
by which seizures could be stopped through elevation
of the bood-pCO2 either via re-breathing [23] or by
carbogen inhalation [24]. Thus, there is preclinical evi-
dence from experimental febrile seizures and case reports
supporting the idea that fever-related respiratory alkalosis
plays a role in the generation of febrile seizures [25]. These
findings and the uncritical safety profile of carbogen,
which has been used for long in various diagnostic proce-
dures, encouraged us to translate these findings into a
controlled interventional clinical trial in a domestic setting
that combines phases I and II – the CARDIF study.
Methods
Study objective
We hypothesize that carbogen administered through a
low-pressure can fitted with a respiratory mask is safe
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ively than placebo (pure oxygen) within 3 minutes.Figure 2 Experimental setting. Assessment of inspiratory &
endtidal pCO2, respiratory volume & rates, air flow velocity &
pressure was done using an artificial lung, a pCO2-sensor, a
pneumotychograph, and an anatomical facsimile of a face with
nasopharynx and oral cavity of a 2 year-old child. Accordingly,
anatomical dead space was adjusted to 40 ml.Application device
In order to verify that inhalation of 6 liters carbogen over
3 minutes through a loosely fitting mask from a low-
pressure can (Figure 1) achieves the required increase of
endtidal pCO2, we tested the device in a respiratory model
and in a human adult volunteer (Figures 2 & 3). The re-
spiratory model was composed of an artificial test lung
(QuickLung®, IngMar Medical, Pittsburgh, PA, USA), air-
ways with adjusted dead space, a pneumotachograph
(Metabo, Epalinges, Switzerland), sidestream capnography
(Microstream® and IntelliVue® MP30, Philips, Hamburg,
Germany) and an anatomical model of the infantile naso-
pharynx. The tidal volume, dead space and the respiratory
frequency were set to several age-specific physiological
values. Breaths were generated by manually pumping
the test lung. During the investigations predefined tidal-
volumes were kept constant by fixing the hub of the test
lung to a certain volume. Frequency was given by a metro-
nome. Resulting respiratory minute-volumes, breathing
rates, air flow, airway pressure and pCO2 before, during
and after carbogen inflation were continuously recorded
with a sampling rate of 50 Hz (ICU-Lab, KleisTEK Engin-
eering, Bari, Italy and ICM+, University of Cambridge,
England). The in vivo test was done with a healthy adult
volunteer, whose endtidal pCO2 was continuously mea-
sured with same sidestream pCO2 device as before, during
and after carbogen inflation. Finally, in order to verify that
breathing from the mask, which always would imply some
degree of re-breathing, did not unduly increase the
endtidal pCO2, the volunteer breathed into the mask with
stopped gas flow while inspiratory and endtidal pCO2 as
well as SaO2 were simultaneously measured.Figure 1 The application device. (A) Low-pressure can containing
6 liter of the study medication with attached, loosely fitting,
“one-size for all” respiratory mask. Pressing on the grey cantilever
initiates the gas flow. (B) Application of the study medication to a
child. The parents are advised to press on the grey cantilever until
the audible gas-flow has stopped (after ≈3 minutes).Study design
The CARDIF study is a monocentric, prospective, double-
blind, placebo-controlled, randomized study. It has been
approved by the Ethical Review Board of the State of
Berlin and the Competent Regulatory Authority, and is
registered at the U.S. Clinical Trials Registration System
(NCT01370044). The detailed study design according to
the revised CONSORT statement [26,27] is described
below (see also Figure 4). The study design had to meet
the following challenges:
Route and method of CO2 application
As febrile seizures usually occur at home, safety and prac-
ticability aspects had to be specifically addressed while
selecting the appropriate method for CO2 delivery. The
pCO2 in human blood may be increased by two methods:
one is to re-breathe exhaled air through a plastic bag (the
re-breathing technique), which is commonly used to treat
acute hyperventilation syndrome and panic disorders
[25,28]. In young infants, however, this technique requires
special expertise as prolonged re-breathing might reduce
inspiratory oxygen concentration and induce hypoxia. Re-
breathing must thus not be applied without the possibility
to measure endtidal pO2 and pCO2 [23]. A second, much
safer method is the application of CO2-enriched air or of
medical carbogen (5% CO2 plus 95% O2), which ensures
that the blood pCO2 does not increase and the pO2 does
not drop beyond certain limits. The added oxygen even
improves oxygenation and prevents hypoxia. As febrile
seizures usually occur at home, where no blood gas moni-
toring is possible, we opted for carbogen to be used in our
clinical trial. For this procedure we developed the concept
Figure 3 Inspiratory and endtidal pCO2 concentrations. (A-B) Course of the inspiratory and endtidal pCO2 using the experimental setting
described in Figure 2. The gas flow was started after 50 seconds and continued for 60 seconds. The experiment was repeated with two different
respiratory rates and tidal volumes: (A) 30/min | 90 ml (corresponding to 2-year-old child) and (B) 40/min | 65 ml (corresponding to a 9-months-old
infant). In both cases we observed an increase of the inspiratory pCO2 by a maximum of ≈20 mmHg. (C-D) In vivo respiration of 6 liter CO2 over 3
minutes: the gas flow was again started at 50 seconds. The panels depict two different experimental conditions: (C) The test person tried to maintain a
respiratory rate of 40/min in synchrony with a metronome over the entire period. Under these conditions the endtidal pCO2 rose by 7 mmHg. In
setting (D) the test person had hyperventilated before the start of the gas flow. Starting from a lower pCO2 of 17 mmHg, the pCO2 again rose by
7 mmHg.
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(Figure 1). The pressurized gas secures high enough flow
rates to obtain the desired intra-tracheal pCO2 (Figure 3).
Biometric design
As the preexisting clinical evidence was limited, we chose
a two phase adaptive design according to Bauer & Köhne
[29], which comprises an adaptive interim analysis to allow
for sample size modifications without compromising the
overall significance level to assure the overall power of the
study.
Randomization
Due to procedural constraints, the randomization can-
not take place while the child has a seizure, but has to
be done immediately after inclusion into the study. As
there is only a 25-30% chance that the included patients
will indeed have a febrile seizure recurrence during the
24 months study period, thrice as many individuals have
to be randomized than will be finally included into the
analysis. The individuals for the analysis will thus be
chosen according to the principle of the “modifiedintention-to-treat population” [30]. Accordingly, only pa-
tients with a febrile seizure recurrence will be analyzed
in the intention-to-treat analysis. A total of 288 patients
will be included into the study, 80 for the first and 208
for the second study phase. We expect to include 20+
52 = 72 patients with febrile seizure recurrences into the
final analysis. This number could be corrected upwards
after completion of the first phase, but not downwards
(see Statistical analysis).
“Crossover” design
After the first seizure recurrence a crossover occurs.
With this, regardless of the result of the first treatment,
patients who received placebo for the first seizure recur-
rence receive verum for the second one or vice versa.
From the third seizure recurrence onwards, all patients
receive open label verum. Since it is anticipated that only
a minority of patients will suffer from a second seizure
recurrence and thus enter the crossover arm, the study
is not a true crossover study. Data from the “crossover”
and the open label extension phase will thus only be
considered for secondary analyses. The primary analysis
Figure 4 Flow diagram of the CARDIF-trial.
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secondary analyses consider all seizure recurrences per
patient.
Primary and secondary outcome
The primary outcome is the efficacy of a 3 minute appli-
cation of carbogen to stop a febrile seizure recurrence.
Secondary outcome parameters are safety, practicability
to use the can, quality of life, contentedness, and anx-
iousness and mobility of the parents.
Treatment failure is defined as a febrile seizure recur-
rence, which has been treated with the study medication
but did not cease within the first 3 minutes, so that the
“standard therapy” (rectal diazepam) has to be applied.
Safety is defined as the number of adverse events. The
practicability to handle the can and mask are assessed by
a questionnaire. Further, parents are asked to report ontheir quality-of-life, contentedness, anxiousness and mo-
bility. These data are gathered in an open interview fol-
lowing standardized study-related questions.Patient population
Patients will be recruited from the Children’s University
Hospital of the Charité in Berlin. Parents or custodians
of potential participants will be thoroughly informed
about the study rationale, procedures, potential risks and
benefits. After written informed consent, children will be
included into the study if all study selection criteria (see
Table 1) are met. The study begins with the randomization
into one of the two arms. Parents are trained hands-on by
the study personnel to assemble the mask and use the can
(Figure 1). This training is complemented by written
instructions.
Table 1 In - and exclusion criteria
Inclusion criteria Exclusion criteria
1. Written informed consent from the parents or custodians of the study
participant.
1. Suspected or proven meningitis or encephalitis as a possible cause for
a past cerebral seizure associated with fever.
2. At least one febrile seizure in the past medical history of the study
participant.
2. Presence of a neurological disease or a brain malformation.
3. Age 12 months—5 years in phase 1 and age 6 months—5 years in
phase 2 of the adaptive design (after observation of 20 seizures,
approximately patients number 81-288).
4. Cerebral seizures without fever in the past medical history.
5. Proof of spike-wave discharges or of a focus in the in the interval EEG.
6. Presence of a respiratory illness (e.g. bronchial asthma or
bronchopulmonary dysplasia, BPD).
7. Presence of other severe organ or chronic diseases.
8. Current participation in another clinical trial.
9. Failure to provide written informed consent on part of the parents or
custodians with regard to the storage and dissemination of
pseudonymized study results.
10. Known adverse reactions against carbogen.
11. Placement of either the child or a parent/custodian in an institution,
based on judicial orders.
12. Lack of understanding of the study procedures on part of the parents
or custodians (e.g. lack of language knowledge or of general intellectual
capacity).
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Carbogen is a gas mixture composed of 5% CO2 and
95% O2, which is stored in compressed gas cylinders
(Figure 1A). These low-pressure cans are manufactured
and filled by the company MTI Industriegase AG (in co-
operation with the Westphalen AG, Germany) and con-
tain 6 liters carbogen gas. A breathing mask with attached
application cantilever and a folded instruction sheet are
shrink-wrapped in plastic foil together with the can. The
amount of gas and the size of the valve are adjusted to
allow an easily audible gas flow of 3 minutes duration. It is
important that the parents realize when the can is empty
in order to apply rectal diazepam (“standard therapy”) if
the seizure recurrence has not stopped within these 3 mi-
nutes of gas application. Carbogen is known to be toler-
ated very well with only little side effects. Some
discomfort has been reported by patients breathing 5%
CO2 for a prolonged period of time [31,32], which was
also seen in healthy volunteers [33]. However, due to the
short application time, effects on normal brain function
and other side effects are expected to be minimal. Patients
suffering from febrile seizures tend to hyperventilate dur-
ing fever, which leads to a pathological reduction of pCO2
in the blood (respiratory alkalosis) [22]. In these patients,
carbogen inhalation would thus not lead to a pathological
pCO2 increase, but restore the physiological normal state.
Therefore, the occurrence of side effects is even less likely
in patients with febrile seizures than in healthy controls.
In addition to 5% carbon dioxide, carbogen gas con-
tains 95% oxygen. The placebo contains 100% oxygen.Oxygen might in principle have a toxic effect due to the
formation of reactive oxygen species (ROS). It should be
noted, however, that the application in the study is very
brief and not hyperbaric. In patients with febrile sei-
zures, oxygen saturation (SaO2) may drop below 90%
during a seizure because of irregular breathing. The add-
itional administration of oxygen would improve the
SaO2 and would be in line with the guidelines [9].
Randomization and treatment allocation
After inclusion into the study, patients will receive a
running patient number. For each patient we reserve a
package containing two blinded cans (“A” and “B”).
Block randomization will be done by issuing to the par-
ents the first blinded “A” can (randomly containing ei-
ther verum or placebo) out of consecutively numbered
packages. After the first seizure recurrence the parents
are issued the “B” can of their package, which contains
verum if “A” was placebo and vice versa. After a second
seizure recurrence the parents will receive further open-
label cans that all contain verum. The study duration
will be 24 months for each patient. Patients who have at
least one seizure recurrence during this time will be in-
cluded into the (modified) intention-to-treat analysis.
Study procedures
At study entry all patients receive a thorough physical
examination. Neurological assessment includes vigilance,
muscle strength and tone, coordination, sensibility, walk-
ing performance und cranial nerve status. Parents are
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had occurred. Hence a study physician “on call” can be
reached round the clock 24/7 by mobile phone, who will
then explain and ask a set of standardized questions
about the seizure. Parents are asked about the circum-
stances and the details of the seizure recurrence including
the date and time, duration, focality, body temperature at
the time of the seizure, cause of the febrile infection and
maximum temperature during the entire febrile period.
Questions regarding the endpoint comprise: (i) cessation
of the seizure during the 3 minute application of the study
medication, or (ii) the necessity to use diazepam there-
after. Further questions are related to side effects, ratings
on the practicability, quality of life, anxiousness, content-
edness and mobility with regard to the use of the can. Par-
ents are further asked to present to the study center as
soon as possible to exchange the study medication. If the
family cannot come to the study center, a study physician
visits the family at home. If parents do not contact the
study center for 6 months, the study team will phone the
family to make sure that no seizure recurrence had oc-
curred in the meantime and to inquire about potential
problems.
The study will be performed in accordance with the
Good Clinical Practice (GCP) guidelines, the Declaration
of Helsinki, the German Medical Drug Law and Data
Protection Laws in their current or effective versions.
An extensive GCP monitoring will be conducted. Add-
itionally, we put strategies in place to maximize data
quality, such as intensive training of the study team,
nursing personal and parents. Adverse event manage-
ment will be done according to standard regulations.
Safety
The overall risk of the study is considered to be minimal.
In the verum group, administration of carbogen will only
reconstitute the normal physiological state. According to
the laws of respiratory physiology it is impossible to
increase the arterial pCO2 to toxic levels with 3 liter
carbogen. Hence, the study-related pCO2-elevation is
only short and normalizes within 30 seconds after ter-
mination of the gas application. The short-term oxygen
application does not bear any risks and even improves
the oxygenation of the patient during the seizure. Finally,
we investigated in an adult volunteer what would hap-
pen if the gas flow ceased while the parents would con-
tinue to hold the mask in front of the child’s face. The
experiment was continued for 6 minutes. After 3 mi-
nutes a small re-breathing effect was observed with ele-
vation of the inspiratory pCO2 by 1-2 mmHg, but no
elevation of endtidal pCO2. The oxygen saturation was
always >97%. Since the breathing mask is only loosely
fitting, ambient air would have enough access to prevent
suffocation.Definition, documentation and reporting of adverse and
serious adverse events follow established conventions and
regulatory requirements. The entire trial will be termi-
nated prematurely in the event that more than 30% of the
patients terminate their participation prematurely for the
following individual reasons: (i) retraction of informed
consent, (ii) subsequent occurrence one or more exclusion
criteria, (iii) occurrence of a suspected unexpected serious
adverse reaction (SUSAR), (iv) non-authorized use of the
study medication as well as non-compliance of the parents
or custodians of the study participant. Furthermore, the
study will be terminated in the event that the risk-benefit
-ratio changes towards a higher risk. Sealed unblinding en-
velopes are available at the study centre. Unblinding for
any reason inevitably results in the exclusion of the pa-
tient. Parents are thoroughly trained by the study phys-
ician about what to do during a seizure or an emergency
situation and when to call an ambulance to present to the
Accident and Emergency Department of the Children’s
University Hospital of the Charité, Berlin. The study team
can be reached by mobile phone around the clock.
Statistical analyses
Statistical planning is based on the modified intention-
to-treat principle, i.e. only patients suffering from a fe-
brile seizure recurrence during the study period of 24
months will be assigned to the intention-to-treat popula-
tion. Analyses will be performed using SPSS, R, and SAS
in their newest versions.
The aim of the study is the proof of the superiority of
the experimental intervention (carbogen) versus control
(oxygen) to suppress a seizure recurrence within 3 mi-
nutes. Success rates under intervention and control be-
ing pI and pK, the statistical null hypothesis is pI = pK,
and the alternative hypothesis pI ≠ pK. The analyses will
be carried out according to Bauer & Köhne with α =
0.025, cα= 0.00380 and α0 = 0.5 (in each case one-sided)
[29]. The main variable “diazepam application “no” ( =
success) versus “yes” (= failure)” will be analyzed as a
binary endpoint by means of the Fisher´s exact test. The
secondary endpoints safety and practicability will be ana-
lyzed by relative frequency and two-sided 95% confi-
dence interval. The other secondary endpoints quality of
life, anxiousness, mobility and contentedness will be an-
alyzed in a descriptive manner according to their scaling;
p-values will be reported but are not to be interpreted in
a confirmatory way. The dependency of the repeated
measures (“crossover” and “open label” phase) will be
adjusted for by means of generalized estimating equation
for a logistic regression model.
One-sided significance level will be 0.025. With an
expected difference of 75% versus 25% the power for the
two-sided Fisher´s exact test will be 86% when including
2 x 26 patients. The effective power will probably be
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not decreased. After 2 x 10 patients with at least one
seizure recurrence have been included, all data of those
patients will be unblinded and will be analyzed with re-
spect to safety. Furthermore, an interim analysis will be
performed to adjust the sample size. A medical expert
will decide whether the safety data allow the continu-
ation of the study. If the study is continued, the new
sample sized will be defined by means of the Bauer &
Köhne method [29].
Ethics
Following the legal requirements, no patient will be de-
prived of standard care due to study participation [34].
The study medication is applied during a time window
of 3 minutes, at which the parents are advised, according
to the guidelines, to wait before application of rectal
diazepam (standard care). If the seizures persists even
after application of diazepam parents are advised to call
the emergency number, as it is the case in standard care.
The study has been reviewed and approved by the
Ethical Review Board of the State of Berlin.
The scheme for recruitment, randomization, and cross-
over of the CARDIF trial is depicted in the Flow diagram
at Figure 4.
Discussion
The CARDIF study will provide important data on a
treatment alternative for patients with febrile seizures
recurrences. This closes the gap between promising pre-
clinical observations and so far missing evidence-based
data on the efficacy and safety of such an approach. Pos-
sibly, the use of benzodiazepines might become dispens-
able or at least second choice behind the application of
carbogen, which has fewer side effects. To our know-
ledge, CARDIF is presently the only registered clinical
trial that investigates a new treatment to suppress an
acute recurrence of a febrile seizure. Since this study is a
non-commercial investigator-initiated trial mainly based
on own preclinical and clinical data, it is a nice example
for an academic translational approach. Some challenges
and limitations of the CARDIF study may deserve a
closer discussion.
Because febrile seizures only occur in children, the
study hypothesis can only be tested in minors. All legal
and ethical criteria specific for the conduct of clinical
trials in minors (e.g. to be of benefit for the entire group
of affected patients and to expose the study participants
to the lowest possible risk and burden) had to be ful-
filled by the study design to obtain regulatory approval.
Before initiating the CARDIF trial we attempted in an-
other study to treat patients with a febrile seizure using
a re-breathing device in a controlled in-patient setting.
As febrile seizures are short unpredicted events andmainly occur at home, we were unable to treat more
than 2 patients over a period of 12 months. As re-
breathing from a plastic bag without safety monitoring
is potentially dangerous, such approach must not be
transferred into a domestic environment.
With this in mind we looked for an alternative and
identified the low-pressure cans, which could be used to
apply the desired amount of carbogen at home. The lim-
ited volume of gas prevents overdosage and the oxygen
offers the added benefit to prevent hypoxia during the
seizure. The main challenge resulting from this change
of strategy was to find a company, which would be will-
ing and certified to produces such cans with mask
containing the gas in “medical quality” according to the
requirements of the German Medical Drug Law.
A possible difficulty of the study results from the do-
mestic use of the study medication. Hence, the primary
outcome will not be assessed by the investigators but by
medical lay persons (here the parents). Thus, the investi-
gators have to rely on the compliance and reliability of
these individuals with regard to correct application of
the gas as well as the reporting of the outcome. Taking
this into account, parents will receive intensive hands-on
training and supervision, and will be contacted or visited
regularly.
Only approximately 25-30% of children with a life his-
tory of one febrile seizure have further ones. Accord-
ingly, thrice as many patients have to be recruited to the
study than needed for the analysis. This includes the in-
formed consent procedure, randomization, distribution
of the study medication, and training. This will lead pre-
dictably to a high percentage of non-treated patients and
non-used study medication.
In conclusion, the CARDIF study represents a prime
example of an intramural translational approach of an
academic institution: researchers from one research con-
sortium working hand-in-hand with clinicians to trans-
late their findings from basic science leading to novel
therapies. This is made possible by the NeuroCure con-
sortium at the Charité that offers an interdisciplinary
forum, training for physician-scientists, protected re-
search time for clinicians, as well as intramural funding
for investigator initiated trials in order to overcome the
common “translational roadblocks” [35,36].
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